This study indicates that c-Met and EPHA7 might be useful prognostic biomarkers, and the presumed myoferlin/c-Met pathway could be a novel therapeutic target in ccRCC. The gene discussed is EPHA7; the disease is nonpapillary renal cell carcinoma.